TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency

Rehana Z. Hussain, Petra C. Cravens, Richard Doelger, Brianne Dentel, Emily Herndon, Nicolas Loof, Peter Tsai, Darin Okuda, Michael K. Racke, Olaf Stuve

Research output: Contribution to journalArticle

Abstract

Objective: Natalizumab blocks α4-integrin-mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4-integrin deficiency. Method: We generated the conditional knock out mouse strain Mx1.Cre+α4-integrinfl/fl, in which the α4-integrin gene is ablated upon treatment with the TLR3 agonist poly I:C. Adoptive transfer of purified lymphocytes from poly I:C-treated Mx1.Cre+α4-integrinfl/fl donors into naive recipients recapitulates immunosuppression under natalizumab. Active experimental autoimmune encephalomyelitis (EAE) in Mx1.Cre+α4-integrinfl/fl mice treated with poly I:C represents immune-reconstitution. Results: Adoptive transfer of T cells from poly I:C treated Mx1.Cre+α4-integrinfl/fl mice causes minimal EAE. The in vitro migratory capability of CD45+ splenocytes from these mice is reduced. In contrast, actively-induced EAE after poly I:C treatment results in full disease susceptibility of Mx1.Cre+ α4-integrinfl/fl mice, and the number and composition of CNS leukocytes is similar to controls. Extravasation of Evans Blue indicates a compromised blood-brain barrier. Poly I:C treatment results in a 2-fold increase in IFNβ transcription in the spinal cord. Interpretation: Our data suggest that TLR3 agonism in the setting of relative α4-integrin deficiency can reestablish CNS immune surveillance in an experimental model. This pathway may present a feasible treatment strategy to treat and prevent PML under natalizumab therapy and should be considered for further experimental evaluation in a controlled setting.

Original languageEnglish (US)
JournalAnnals of Clinical and Translational Neurology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Poly I-C
Integrins
Mental Competency
Central Nervous System
Autoimmune Experimental Encephalomyelitis
Adoptive Transfer
Brain Diseases
Leukocytes
Toll-Like Receptor 3
Therapeutics
Evans Blue
Interferon Type I
Disease Susceptibility
Opportunistic Infections
Virus Diseases
Blood-Brain Barrier
Knockout Mice
Immunosuppression
Interferons
Multiple Sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency. / Hussain, Rehana Z.; Cravens, Petra C.; Doelger, Richard; Dentel, Brianne; Herndon, Emily; Loof, Nicolas; Tsai, Peter; Okuda, Darin; Racke, Michael K.; Stuve, Olaf.

In: Annals of Clinical and Translational Neurology, 01.01.2018.

Research output: Contribution to journalArticle

Hussain, Rehana Z. ; Cravens, Petra C. ; Doelger, Richard ; Dentel, Brianne ; Herndon, Emily ; Loof, Nicolas ; Tsai, Peter ; Okuda, Darin ; Racke, Michael K. ; Stuve, Olaf. / TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency. In: Annals of Clinical and Translational Neurology. 2018.
@article{d0ddca80d48e46b485971466bdca7ceb,
title = "TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency",
abstract = "Objective: Natalizumab blocks α4-integrin-mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4-integrin deficiency. Method: We generated the conditional knock out mouse strain Mx1.Cre+α4-integrinfl/fl, in which the α4-integrin gene is ablated upon treatment with the TLR3 agonist poly I:C. Adoptive transfer of purified lymphocytes from poly I:C-treated Mx1.Cre+α4-integrinfl/fl donors into naive recipients recapitulates immunosuppression under natalizumab. Active experimental autoimmune encephalomyelitis (EAE) in Mx1.Cre+α4-integrinfl/fl mice treated with poly I:C represents immune-reconstitution. Results: Adoptive transfer of T cells from poly I:C treated Mx1.Cre+α4-integrinfl/fl mice causes minimal EAE. The in vitro migratory capability of CD45+ splenocytes from these mice is reduced. In contrast, actively-induced EAE after poly I:C treatment results in full disease susceptibility of Mx1.Cre+ α4-integrinfl/fl mice, and the number and composition of CNS leukocytes is similar to controls. Extravasation of Evans Blue indicates a compromised blood-brain barrier. Poly I:C treatment results in a 2-fold increase in IFNβ transcription in the spinal cord. Interpretation: Our data suggest that TLR3 agonism in the setting of relative α4-integrin deficiency can reestablish CNS immune surveillance in an experimental model. This pathway may present a feasible treatment strategy to treat and prevent PML under natalizumab therapy and should be considered for further experimental evaluation in a controlled setting.",
author = "Hussain, {Rehana Z.} and Cravens, {Petra C.} and Richard Doelger and Brianne Dentel and Emily Herndon and Nicolas Loof and Peter Tsai and Darin Okuda and Racke, {Michael K.} and Olaf Stuve",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/acn3.664",
language = "English (US)",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency

AU - Hussain, Rehana Z.

AU - Cravens, Petra C.

AU - Doelger, Richard

AU - Dentel, Brianne

AU - Herndon, Emily

AU - Loof, Nicolas

AU - Tsai, Peter

AU - Okuda, Darin

AU - Racke, Michael K.

AU - Stuve, Olaf

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Natalizumab blocks α4-integrin-mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4-integrin deficiency. Method: We generated the conditional knock out mouse strain Mx1.Cre+α4-integrinfl/fl, in which the α4-integrin gene is ablated upon treatment with the TLR3 agonist poly I:C. Adoptive transfer of purified lymphocytes from poly I:C-treated Mx1.Cre+α4-integrinfl/fl donors into naive recipients recapitulates immunosuppression under natalizumab. Active experimental autoimmune encephalomyelitis (EAE) in Mx1.Cre+α4-integrinfl/fl mice treated with poly I:C represents immune-reconstitution. Results: Adoptive transfer of T cells from poly I:C treated Mx1.Cre+α4-integrinfl/fl mice causes minimal EAE. The in vitro migratory capability of CD45+ splenocytes from these mice is reduced. In contrast, actively-induced EAE after poly I:C treatment results in full disease susceptibility of Mx1.Cre+ α4-integrinfl/fl mice, and the number and composition of CNS leukocytes is similar to controls. Extravasation of Evans Blue indicates a compromised blood-brain barrier. Poly I:C treatment results in a 2-fold increase in IFNβ transcription in the spinal cord. Interpretation: Our data suggest that TLR3 agonism in the setting of relative α4-integrin deficiency can reestablish CNS immune surveillance in an experimental model. This pathway may present a feasible treatment strategy to treat and prevent PML under natalizumab therapy and should be considered for further experimental evaluation in a controlled setting.

AB - Objective: Natalizumab blocks α4-integrin-mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4-integrin deficiency. Method: We generated the conditional knock out mouse strain Mx1.Cre+α4-integrinfl/fl, in which the α4-integrin gene is ablated upon treatment with the TLR3 agonist poly I:C. Adoptive transfer of purified lymphocytes from poly I:C-treated Mx1.Cre+α4-integrinfl/fl donors into naive recipients recapitulates immunosuppression under natalizumab. Active experimental autoimmune encephalomyelitis (EAE) in Mx1.Cre+α4-integrinfl/fl mice treated with poly I:C represents immune-reconstitution. Results: Adoptive transfer of T cells from poly I:C treated Mx1.Cre+α4-integrinfl/fl mice causes minimal EAE. The in vitro migratory capability of CD45+ splenocytes from these mice is reduced. In contrast, actively-induced EAE after poly I:C treatment results in full disease susceptibility of Mx1.Cre+ α4-integrinfl/fl mice, and the number and composition of CNS leukocytes is similar to controls. Extravasation of Evans Blue indicates a compromised blood-brain barrier. Poly I:C treatment results in a 2-fold increase in IFNβ transcription in the spinal cord. Interpretation: Our data suggest that TLR3 agonism in the setting of relative α4-integrin deficiency can reestablish CNS immune surveillance in an experimental model. This pathway may present a feasible treatment strategy to treat and prevent PML under natalizumab therapy and should be considered for further experimental evaluation in a controlled setting.

UR - http://www.scopus.com/inward/record.url?scp=85055688636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055688636&partnerID=8YFLogxK

U2 - 10.1002/acn3.664

DO - 10.1002/acn3.664

M3 - Article

C2 - 30564621

AN - SCOPUS:85055688636

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

ER -